Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivoceranib - Jiangsu Hengrui Medicine Co/LSK Biopharma

Drug Profile

Rivoceranib - Jiangsu Hengrui Medicine Co/LSK Biopharma

Alternative Names: Aitan; Apatinib; Apatinib mesylate; YN-968-D1

Latest Information Update: 12 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Fudan University Shanghai Cancer Center; Jiangsu Hengrui Medicine Co.; LSK Biopharma; Peking University People's Hospital; The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Amides; Antineoplastics; Cyclopentanes; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Liver cancer; Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Osteosarcoma; Solid tumours
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 04 Jan 2019 Jiangsu HengRui Medicine plans a phase II trial for Liver cancer (Combination therapy, Inoperable/Unresectable) (NCT03793725)
  • 01 Dec 2018 Jiangsu HengRui Medicine plans a phase III trial for Liver cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) (PO) (NCT03764293)
  • 24 Oct 2018 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater, Late-stage disease) in South Korea (PO) (NCT03707028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top